Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs J B Hunt Transport Services Inc (JBHT) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
J B Hunt Transport Services IncTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs J B Hunt Transport Services Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.4 (market cap $5.07B), while J B Hunt Transport Services Inc trades at $271.73 (market cap $24.92B). The key difference: J B Hunt Transport Services Inc is far larger — about 4.9× ACADIA Pharmaceuticals Inc.'s market cap, and J B Hunt Transport Services Inc pays a 0.68% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.

ACADJBHT
Market Cap
$5.07B$24.92B
Sector
HealthIndustrials
52-Week High
$29.41$298.41
52-Week Low
$20.06$130.65
Enterprise Value
$4.19B$26.06B
Dividend Yield
0.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.

Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.

J B Hunt Transport Services Inc

JBHT stock trades at $266.14, down 0.89% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue trends show stabilization after a decline from 2022 peaks, while profitability metrics like ROE at 18.45% and net margin at 5.31% reflect efficient operations. Recent news highlights the company's 65th anniversary and partnerships to enhance freight technology.

The outlook is positive with a consensus price target of $299.82, implying 12.6% upside, supported by analyst buy ratings (57.78%). Risks include economic sensitivity impacting freight demand and competitive pressures. Earnings execution and intermodal demand recovery are key catalysts for stock appreciation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About J B Hunt Transport Services Inc

J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).

Read more on JBHT